Abstract
Despite therapeutic improvements, all patients (pts) sooner or later acquire resistance to CDK4/6 inhibitors. Mutations in KRAS have been thought to be the main cause of resistance in several cancers, but have not been analysed extensively in breast cancer in the era of Palbociclib+Fulvestrant (P+F). In our study, using liquid biopsy, we correlated the emerging KRAS-mutated ctDNA and overexpression of CDK9 with resistance to P+F as first line metastatic treatment in HR+/HER2-Metastatic Breast Cancer (MBC).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
